Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications

Immune checkpoint inhibitors (ICIs) have transformed the treatment of a broad range of malignancies over the past decade. As the scope of indications and the clinical experience expands, oncologists are increasingly confronted with complex scenarios. This chapter addresses three of the most clinically challenging frontiers in ICI use: the safe and effective application of checkpoint blockade in patients with preexisting autoimmune disease, the evolving toxicity landscape of ICI-based combination regimens including chemotherapy + immune checkpoint inhibition, immune checkpoint inhibition + tyrosine kinase inhibitor, and immune checkpoint inhibition + antibody-drug conjugate, and the emerging evidence supporting ICI in solid organ transplant recipients with advanced malignancies.